KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Cash from Operations (2016 - 2025)

Historic Cash from Operations for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $7.0 billion.

  • AbbVie's Cash from Operations rose 2895.17% to $7.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 billion, marking a year-over-year increase of 2634.0%. This contributed to the annual value of $18.8 billion for FY2024, which is 1765.84% down from last year.
  • According to the latest figures from Q3 2025, AbbVie's Cash from Operations is $7.0 billion, which was up 2895.17% from $5.2 billion recorded in Q2 2025.
  • AbbVie's 5-year Cash from Operations high stood at $7.9 billion for Q3 2021, and its period low was $1.6 billion during Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was $5.1 billion (2021), whereas its average is $5.4 billion.
  • In the last 5 years, AbbVie's Cash from Operations plummeted by 6406.08% in 2024 and then surged by 12690.44% in 2025.
  • AbbVie's Cash from Operations (Quarter) stood at $5.1 billion in 2021, then surged by 46.36% to $7.4 billion in 2022, then tumbled by 36.01% to $4.8 billion in 2023, then skyrocketed by 48.29% to $7.0 billion in 2024, then dropped by 0.34% to $7.0 billion in 2025.
  • Its last three reported values are $7.0 billion in Q3 2025, $5.2 billion for Q2 2025, and $1.6 billion during Q1 2025.